Human Genome Sciences, Inc.

Other

Smithkline Beecham Corporation

The Institute for Genomic Research

Human Genone Sciences, Inc.

Lisa M Fitzgerald

Mark D Adams

Claire M Fraser

Ewen F Kirkness

Gregg A Hastings

Judith A Blake

Fred H Drake

Norman H Lee

Maxine Gowan

Haodong Li

Christine Marie Debouck

Julie A Rood

Maxine Gowen

Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.

Human osteoclast derived cathepsin

Human osteoclast-derived cathepsin

Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases. A patient is treated by administering an antibody produced against a polypeptide consisting of SEQ ID NO: 2.

Treatment of a patient by administering an antibody that inhibits cathepsin O

The present invention relates to a human MIF-3 and DNA (RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonists against such polypeptide. Also provided are methods of using the polypeptide therapeutically for treating cancer, infections, acceleration of wound healing, stimulating the immune system, as an anti-inflammatory. Methods of using antibodies and antagonists for therapeutic purposes, is also disclosed, for example, for treating lethal endotoxaemia, ocular inflammation and diagnosing immune diseases. Also disclosed are diagnostic methods for detecting conditions related to a mutation in a nucleic acid sequence encoding a polypeptide of the present invention and altered levels of the polypeptide of the present invention.

Macrophage Migration Inhibitory Factor-3

The invention relates to cathepsin K polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

Cathepsin K gene

Macrophage migration inhibitory factor-3

Growing community of inventors

Germantown, MD, United States of America

Lisa M Fitzgerald